Clinical trials: Dementia Disorders
Huntington's Disease
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
The study is designed as a multi-site, prospective, 15-month longitudinal, cohort study measuring CSF mHTT in participants with early manifest Stage I or Stage II Huntington's Disease (HD).
- Trial name
- NCT03664804
- Testing
- No Study Drug was Administered in this Study
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Dementia, Family Caregiver
German Adaptation of REACH II
The purpose of the present study is to adapt, to implement and to evaluate an support program for family caregivers of patients suffering from Alzheimers'Disease (AD).
- Trial name
- GE-REACH (NCT01690117)
- Testing
- GE-REACH-program
- Where
- Germany
- Volunteers
- 92 people
- Sponsor
- University of Leipzig
Caregiver Burnout
CuidaTXT: a Text Message Dementia-caregiver Intervention for Latinos
Latino families with dementia experience substantial disparities in access to caregiver support compared to their non-Latino white peers, putting them at an increased risk for negative emotional, physical and financial outcomes.
- Trial name
- CuidaTXT (NCT04316104)
- Testing
- CuidaTXT
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Huntington Disease, Chorea
Atomoxetine and Huntington's Disease
The purpose of this research study is to evaluate the effect of atomoxetine (also known as Strattera) compared to placebo (inactive substance) on daily activities such as attention and focus, thinking ability and muscle movements…
- Trial name
- NCT00368849
- Testing
- atomoxetine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Iowa
Alzheimer's Disease
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in older persons with mild Alzheimer's disease.
- Trial name
- NCT01374438
- Testing
- MSDC-0160
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Metabolic Solutions Development Company
Huntington Disease
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
- Trial name
- NCT05358821
- Testing
- SAGE-718
- Where
- 14 sites in United States, Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Huntington Disease
Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease
Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a prospective, phase II, single-center, randomized (2:2:1), triple-blind, placebo controlled study, with two test doses of Cellavita HD product.
- Trial name
- ADORE-DH (NCT03252535)
- Testing
- Cellavita HD lower dose, Cellavita HD higher dose
- Where
- Brazil
- Volunteers
- 49 people
- Sponsor
- Azidus Brasil
Agitation
Treating Acutely Agitated Patients With Asenapine Sublingual Tablets
Our proposal is to administer asenapine to patients who are clinically agitated and in need of immediate intervention. At present there are no controlled studies that we know of that explores the use of asenapine for this…
- Trial name
- NCT01400113
- Testing
- Asenapine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Unity Health Toronto
Alzheimer's Disease
A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease.
- Trial name
- NCT02431468
- Testing
- Bryostatin 1
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Neurotrope Bioscience, Inc.
Mild Cognitive Impairment, Healthy Aging
SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting
The goal of this study is to test efficacy and safety of person-centered, culturally-informed protocols for disclosure of different combinations of Alzheimer's dementia risk factors.
- Trial name
- SHARE(D) (NCT04309500)
- Testing
- Personalized DAT Risk Disclosure Protocol
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Huntington's Disease
Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
The pace of basic science research defining the mechanisms of selective neuronal degeneration in Huntington disease (HD) has far exceeded the pace of translation of this information into clinically effective treatments for the…
- Trial name
- HD (NCT00670709)
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Alzheimer Disease, Dementia
MEMORI Corps: Activity-based Companion Care for Dementia
This project adapts a novel activity-based companion care model, the Making Engagement Meaningful through Organized Routine Interaction (MEMORI) Corps intervention, for a virtual delivery format, and then implements the…
- Trial name
- MEMORI Corps (NCT03896711)
- Testing
- MEMORI Corps program, Augmented Waitlist Control
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Dementia
Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia
This study will employ a double-blind, placebo-controlled approach to assess the effect of 1072nm infrared (IR) phototherapy on the behavioral and cognitive symptoms associated with early and mid-stage dementia.
- Trial name
- NCT01059877
- Testing
- 1072nm infrared Photobiomodulation, Photobiomodulation SIMULATED
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Quietmind Foundation
OSA, Sleep Apnea
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
Obstructive sleep apnea (OSA) is common in older adults and has recently been implicated in pathogenesis of Alzheimer's disease (AD). Research has shown that sleep disruptions have caused memory impairment.
- Conditions
- OSA, Sleep Apnea, Obstructive Sleep Apnea, Alzheimer Disease
- Trial name
- NCT05094271
- Testing
- Supplemental Oxygen, Continuous Positive Airway Pressure Machine, Room Air
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- University of California, San Diego
Dementia, Depression
Testing the Feasibility of the Individualized Positive Psychosocial Intervention (IPPI)
The goal of this clinical trial is to test the feasibility of the Individualized Positive Psychosocial Interaction (IPPI) with 108 nursing home residents living with dementia and distress or depressive symptoms.
- Conditions
- Dementia, Depression, Behavior
- Trial name
- IPPI (NCT05980299)
- Testing
- Individualized Positive Psychosocial Interaction
- Where
- 7 sites in United States
- Volunteers
- 200 people
- Sponsor
- Miami University
Alzheimer Disease
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease
The study was performed to compare the safety and efficacy of Cerebrolysin (10 mililiters [ml]), Aricept (10 miligrams [mg]), and a combination of both treatments on cognitive performance and global function in patients with…
- Trial name
- Combi (NCT00911807)
- Testing
- Cerebrolysin + donepezil
- Where
- 3 sites in Spain
- Volunteers
- 217 people
- Sponsor
- Ever Neuro Pharma GmbH
Alzheimer's Disease
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease
- Trial name
- NCT01735630
- Testing
- ELND005
- Where
- 70 sites in United States, Canada and 2 more
- Volunteers
- 350 people
- Sponsor
- OPKO Health, Inc.
Alzheimer Disease
Tau Screening Study in Subjects With Early Symptomatic AD
This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron…
- Trial name
- NCT03467477
- Testing
- Flortaucipir F18, Brain PET Scan
- Where
- 9 sites in United States
- Volunteers
- 161 people
- Sponsor
- Avid Radiopharmaceuticals
Primary Progressive Aphasia, MCI
tDCS Intervention in Primary Progressive Aphasia
Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. Mild cognitive impairment (MCI) is slowly progressive decline in a single domain of cognition (e.g.
- Conditions
- Primary Progressive Aphasia, MCI, FTD
- Trial name
- NCT02606422
- Testing
- Active HD-tDCS plus Speech-Language Therapy
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Dementia, Mild Cognitive Impairment
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment
This study aims to develop and evaluate new in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias…
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT04206670
- Testing
- In-Home Technology System and Questionnaires, Waiting Control In-Home Technology System and Questionnaires
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley